Key result
Erythromycin decreases warfarin clearance by ~14%, especially in subjects with slow baseline clearance.
Why the study?
Erythromycin's potentiation of warfarin and its effect on warfarin kinetics were not well defined.
Does erythromycin alter the disposition kinetics of warfarin in normal subjects?
Does erythromycin alter the disposition kinetics of warfarin in normal subjects?
Effect estimate: 14% decrease
p-value: p=<0.001
Erythromycin potentiates warfarin by slowing its clearance, highlighting a clinically significant drug-drug interaction that requires monitoring.
May warrant INR monitoring during coadministration; leaves open confirmation of clinical impact in anticoagulated patients.
Erythromycin is generally regarded as innocuous in regard to adverse interactions with other drugs. Recently, however, its potentiation of theophylline and warfarin has been reported. The present investigation defined more specifically the kinetics of the interaction between erythromycin and warfarin. Warfarin kinetics were evaluated in 12 normal subjects who took a single 1 mg/kg dose of warfarin with and without erythromycin. Erythromycin (250 mg p.o.) every 6 h for 8 days decreased warfarin clearance by 14% (p less than 0.001). Warfarin's apparent volume of distribution was not affected. Further, the effect of erythromycin was greatest among subjects whose control phase warfarin clearance was relatively slow, and least among those whose control phase warfarin clearance was relatively fast. The magnitude of the decrease in warfarin clearance correlated negatively with control warfarin clearance (r = -0.89, p less than 0.005). These data are consistent with the interpretation that erythromycin can potentiate warfarin-induced hypoprothrombinemia by slowing warfarin clearance.
No takes yet. Share an insight, caveat, or question.
Bachmann et al. (2008) studied Healthy volunteers (n=12). Erythromycin vs. Without erythromycin was evaluated on Warfarin clearance (14% decrease, p=<0.001). Erythromycin decreased warfarin clearance by 14% (p<0.001), with the greatest effect observed in subjects with relatively slow baseline clearance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: